Elritercept alone or with ruxolitinib for myelofibrosis
Treatments studied
Part of Blood & lymphatic clinical trials.
This Phase 2 trial tests whether elritercept, given alone or together with ruxolitinib, can improve symptoms and disease control in adults with myelofibrosis. It may help people who have anemia and either cannot tolerate, can’t get enough benefit from, or are already using ruxolitinib.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older and can sign consent and allow use of your health information.
- You have myelofibrosis: primary myelofibrosis, or myelofibrosis after polycythemia vera or essential thrombocythemia.
- Your daily functioning is limited but not too severe (ECOG 0 to 2).
- Your doctor expects you to live at least 12 months.
- You have anemia based on specific hemoglobin levels and/or recent red blood cell transfusions.
- You fit one study “arm,” such as having prior JAK-inhibitor treatment that was stopped, or being on ruxolitinib steadily, or (Brazil only) meeting extra symptom/spleen size rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new drug called elritercept can help reduce the need for blood transfusions in adults with myelofibrosis (a bone marrow cancer) who are already taking ruxolitinib. The goal is to see if elritercept helps your body make more red blood cells naturally.
This trial tests a new combination of two drugs, ruxolitinib and ulixertinib, for people with myelofibrosis whose disease is not fully controlled by ruxolitinib alone. The goal is to see if adding ulixertinib can improve spleen enlargement, symptoms, or bone marrow changes.
This trial tests whether adding TL-895 to ruxolitinib can improve outcomes in adults with myelofibrosis. It focuses on people who are not getting enough benefit from ruxolitinib or who need treatment as part of the study.
This trial tests whether adding a drug called interferon alfa-2b to the standard treatment ruxolitinib can help people with myelofibrosis. It may reduce spleen size and improve blood counts.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
This trial tests a new drug called revumenib, which is being studied for people with myelofibrosis. Revumenib may help slow the disease and improve symptoms. The study has two parts: one for people who have already tried a JAK inhibitor, and one for those currently on a JAK inhibitor but still have active disease.
Hear when a new Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.